219 related articles for article (PubMed ID: 25202075)
1. Matrix metalloproteinase-2 and -14 in p16-positive and -negative HNSCC after exposure To 5-FU and docetaxel In Vitro.
Aderhold C; Umbreit C; Faber A; Birk R; Sommer JU; Hörmann K; Schultz JD
Anticancer Res; 2014 Sep; 34(9):4929-37. PubMed ID: 25202075
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapeutic alteration of VEGF, PDGF and PDGFRα/β expression under 5-FU vs. docetaxel in HPV-transformed squamous cell carcinoma compared to HPV-negative HNSCC in vitro.
Aderhold C; Umbreit C; Faber A; Sauter A; Sommer JU; Birk R; Erben P; Hofheinz RD; Stern-Straeter J; Hörmann K; Schultz JD
Anticancer Res; 2013 May; 33(5):1951-61. PubMed ID: 23645743
[TBL] [Abstract][Full Text] [Related]
3. Imatinib-associated matrix metalloproteinase suppression in p16-positive squamous cell carcinoma compared to HPV-negative HNSCC cells in vitro.
Umbreit C; Aderhold C; Faber A; Sauter A; Hofheinz RD; Stern-Straeter J; Hoermann K; Schultz JD
Oncol Rep; 2014 Aug; 32(2):668-76. PubMed ID: 24890748
[TBL] [Abstract][Full Text] [Related]
4. Unexpected alteration of β-catenin and c-KIT expression by 5-FU and docetaxel in p16-positive squamous cell carcinoma compared to HPV-negative HNSCC cells in vitro.
Umbreit C; Aderhold C; Faber A; Sommer JU; Sauter A; Hofheinz RD; Stern-Sträter J; Hoermann K; Schultz JD
Anticancer Res; 2013 Jun; 33(6):2457-65. PubMed ID: 23749896
[TBL] [Abstract][Full Text] [Related]
5. Alteration of MMP-2 and -14 expression by imatinib in HPV-positive and -negative squamous cell carcinoma.
Faber A; Sauter A; Hoedt S; Hoermann K; Erben P; Hofheinz RD; Sommer U; Stern-Straeter J; Schultz DJ
Oncol Rep; 2012 Jul; 28(1):172-8. PubMed ID: 22576800
[TBL] [Abstract][Full Text] [Related]
6. Targeting mTOR and AREG with everolimus, sunitinib and sorafenib in HPV-positive and -negative SCC.
Aderhold C; Faber A; Umbreit C; Birk R; Weiss C; Sommer JU; Hörmann K; Schultz JD
Anticancer Res; 2015 Apr; 35(4):1951-9. PubMed ID: 25862847
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapeutic alteration of β-catenin and c-kit expression by imatinib in p16-positive squamous cell carcinoma compared to HPV-negative HNSCC cells in vitro.
Schultz JD; Sommer JU; Hoedt S; Erben P; Hofheinz RD; Faber A; Thorn C; Hörmann K; Sauter A
Oncol Rep; 2012 Jan; 27(1):270-80. PubMed ID: 21993766
[TBL] [Abstract][Full Text] [Related]
8. Small molecule-based chemotherapeutic approach in p16-positive and -negative HNSCC in vitro.
Aderhold C; Faber A; Grobschmidt GM; Chakraborty A; Bockmayer A; Umbreit C; Birk R; Stern-Straeter J; Hörmann K; Schultz JD
Anticancer Res; 2013 Dec; 33(12):5385-93. PubMed ID: 24324073
[TBL] [Abstract][Full Text] [Related]
9. Livin enhances chemoresistance in head and neck squamous cell carcinoma.
Yoon TM; Kim SA; Lee DH; Lee JK; Park YL; Lee KH; Chung IJ; Joo YE; Lim SC
Oncol Rep; 2017 Jun; 37(6):3667-3673. PubMed ID: 28440463
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapeutic alteration of VEGF-/PDGF- and PDGF-Rα/β expression by imatinib in HPV-transformed squamous cell carcinoma compared to HPV-negative HNSCC in vitro.
Schultz JD; Mühlheim K; Erben P; Hofheinz RD; Faber A; Thorn C; Sommer JU; Hörmann K; Sauter A
Oncol Rep; 2011 Nov; 26(5):1099-109. PubMed ID: 21805039
[TBL] [Abstract][Full Text] [Related]
11. Small molecules alter VEGFR and PTEN expression in HPV-positive and -negative SCC: new hope for targeted-therapy.
Aderhold C; Faber A; Umbreit C; Chakraborty A; Bockmayer A; Birk R; Sommer JU; Hörmann K; Schultz JD
Anticancer Res; 2015 Mar; 35(3):1389-99. PubMed ID: 25750290
[TBL] [Abstract][Full Text] [Related]
12. The efficacy of induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil combined with cisplatin concurrent chemoradiotherapy for locally advanced head and neck squamous cell carcinoma: a matched pair analysis.
Teo M; Karakaya E; Young CA; Dyker KE; Coyle C; Sen M; Prestwich RJ
Clin Oncol (R Coll Radiol); 2013 Nov; 25(11):647-53. PubMed ID: 23948462
[TBL] [Abstract][Full Text] [Related]
13. Combinatorial Effects of Curcumin with an Anti-Neoplastic Agent on Head and Neck Squamous Cell Carcinoma Through the Regulation of EGFR-ERK1/2 and Apoptotic Signaling Pathways.
Sivanantham B; Sethuraman S; Krishnan UM
ACS Comb Sci; 2016 Jan; 18(1):22-35. PubMed ID: 26505786
[TBL] [Abstract][Full Text] [Related]
14. Targeted Therapies in HPV-positive and -negative HNSCC - Alteration of EGFR and VEGFR-2 Expression In Vitro.
Kramer B; Hock C; Birk R; Sauter A; Stuck BA; Hörmann K; Schultz JD; Aderhold C
Anticancer Res; 2016 Jun; 36(6):2799-807. PubMed ID: 27272791
[TBL] [Abstract][Full Text] [Related]
15. Effect of selective small molecule inhibitors on MMP-9 and VEGFR-1 expression in p16-positive and -negative squamous cell carcinoma.
Kramer B; Schultz JD; Hock C; Sauter A; Stuck BA; Hörmann K; Birk R; Aderhold C
Oncol Lett; 2017 May; 13(5):3269-3276. PubMed ID: 28521433
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of expression of membrane type 1 matrix metalloproteinase and matrix metalloproteinase-2 in human head and neck squamous cell carcinoma.
Imanishi Y; Fujii M; Tokumaru Y; Tomita T; Kanke M; Kanzaki J; Kameyama K; Otani Y; Sato H
Hum Pathol; 2000 Aug; 31(8):895-904. PubMed ID: 10987249
[TBL] [Abstract][Full Text] [Related]
17. Expression of matrix metalloproteinase 1, matrix metalloproteinase 2, and matrix metalloproteinase 9 in carcinoma of the head and neck.
Franchi A; Santucci M; Masini E; Sardi I; Paglierani M; Gallo O
Cancer; 2002 Nov; 95(9):1902-10. PubMed ID: 12404284
[TBL] [Abstract][Full Text] [Related]
18. STAT3 blockade enhances the efficacy of conventional chemotherapeutic agents by eradicating head neck stemloid cancer cell.
Bu LL; Zhao ZL; Liu JF; Ma SR; Huang CF; Liu B; Zhang WF; Sun ZJ
Oncotarget; 2015 Dec; 6(39):41944-58. PubMed ID: 26556875
[TBL] [Abstract][Full Text] [Related]
19. Epidermal growth factor-induced pyruvate dehydrogenase kinase 1 expression enhances head and neck squamous cell carcinoma metastasis
Hsu JY; Chang JY; Chang KY; Chang WC; Chen BK
FASEB J; 2017 Oct; 31(10):4265-4276. PubMed ID: 28596235
[TBL] [Abstract][Full Text] [Related]
20. Down-regulation of MMP-2 expression due to inhibition of receptor tyrosine kinases by imatinib and carboplatin in HNSCC.
Schultz JD; Rotunno S; Erben P; Sommer JU; Anders C; Stern-Straeter J; Hofheinz RD; Hörmann K; Sauter A
Oncol Rep; 2011 Apr; 25(4):1145-51. PubMed ID: 21249321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
